Gilmore A, Valentijn A, Wang P, Ranger A, Bundred N, O'Hare M, Wakeling A, Korsmeyer S, Streuli C: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem. 2002, 277: 27643-27650. 10.1074/jbc.M108863200.
Article
CAS
PubMed
Google Scholar
Olayioye M, Neve R, Lane H, Hynes N: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093/emboj/19.13.3159.
Article
CAS
PubMed
PubMed Central
Google Scholar
Shawver L, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9.
Article
CAS
PubMed
Google Scholar
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19: 6550-6565. 10.1038/sj.onc.1204082.
Article
CAS
PubMed
Google Scholar
Van Obberghen E, Baron V, Delahaye L, Emanuelli B, Filippa N, Giorgetti-Peraldi S, Lebrun P, Mothe-Satney I, Peraldi P, Rocchi S, Sawka-Verhelle D, Tartare-Deckert S, Giudicelli J: Surfing the insulin signaling web. Eur J Clin Invest. 2001, 31: 966-977. 10.1046/j.1365-2362.2001.00896.x.
Article
CAS
PubMed
Google Scholar
Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000, 2: 170-175. 10.1186/bcr50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Igney F, Krammer P: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002, 2: 277-288. 10.1038/nrc776.
Article
CAS
PubMed
Google Scholar
Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002, 2: 183-192. 10.1016/S1535-6108(02)00127-7.
Article
CAS
PubMed
Google Scholar
Bonni A, Brunet A, West A, Datta S, Takasu M, Greenberg M: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999, 286: 1358-1362. 10.1126/science.286.5443.1358.
Article
CAS
PubMed
Google Scholar
Shimamura A, Ballif B, Richards S, Blenis J: Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol. 2000, 10: 127-135. 10.1016/S0960-9822(00)00310-9.
Article
CAS
PubMed
Google Scholar
Zhou X, Liu Y, Payne G, Lutz R, Chittenden T: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem. 2000, 275: 25046-25051. 10.1074/jbc.M002526200.
Article
CAS
PubMed
Google Scholar
Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg M: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.
Article
CAS
PubMed
Google Scholar
Harada H, Andersen J, Mann M, Terada N, Korsmeyer S: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001, 98: 9666-9670. 10.1073/pnas.171301998.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dramsi S, Scheid M, Maiti A, Hojabrpour P, Chen X, Schubert K, Goodlett D, Aebersold R, Duronio V: Identification of a novel phosphorylation site, Ser-170, as a regulator of bad pro-apoptotic activity. J Biol Chem. 2002, 277: 6399-6405. 10.1074/jbc.M109990200.
Article
CAS
PubMed
Google Scholar
Zha J, Harada H, Yang E, Jockel J, Korsmeyer S: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996, 87: 619-628. 10.1016/S0092-8674(00)81382-3.
Article
CAS
PubMed
Google Scholar
Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata J, Wang H, Shabaik A, Tudor G, Krajewski S, Myers T, Johnson G, Sausville E, Reed J: Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol. 1998, 152: 51-61.
CAS
PubMed
PubMed Central
Google Scholar
Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001, 7: 2958-2970.
CAS
PubMed
Google Scholar
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev. 2001, 21: 499-512. 10.1002/med.1022.
Article
CAS
PubMed
Google Scholar
Lynch D, Yang X: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002, 29: 47-50. 10.1053/sonc.2002.31522.
Article
CAS
PubMed
Google Scholar
Brandt R, Wong A, Hynes N: Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene. 2001, 20: 5459-5465. 10.1038/sj.onc.1204709.
Article
CAS
PubMed
Google Scholar
Bruns C, Solorzano C, Harbison M, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler I: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60: 2926-2935.
CAS
PubMed
Google Scholar
Holinger E, Chittenden T, Lutz R: Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem. 1999, 274: 13298-13304. 10.1074/jbc.274.19.13298.
Article
CAS
PubMed
Google Scholar
Cosulich S, Worrall V, Hedge P, Green S, Clarke P: Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol. 1997, 7: 913-920. 10.1016/S0960-9822(06)00410-6.
Article
CAS
PubMed
Google Scholar
Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell. 2002, 9: 1005-1016.
Article
CAS
PubMed
Google Scholar